Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus GVS.
GENTAFAIR vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
GVS is not a recognized drug. No mechanism of action available.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic